Polymorphisms in CYP19A1 and NFKB1 genes are associated with cutaneous melanoma risk in southern Brazilian patients

Melanoma Research

Volumn 26, Issue 4, 2016, Pages 348-353

  Escobar, Gabriela F ^a,c   Arraes, Jose Aroldo A ^d   Bakos, Lucio ^a,c   Ashton Prolla, Patricia ^b,c   Giugliani, Roberto ^b   Callegari Jacques, Sidia Maria ^b   Santos, Sidney ^d   Bakos, Renato M ^a,c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c Postgraduate Programme in Medical Sciences   (Brazil)

^d FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

Brazil; cutaneous melanoma; CYP19A1; genetic polymorphisms; NFKB1

Indexed keywords

AROMATASE; GENOMIC DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; CYP19A1 PROTEIN, HUMAN; NFKB1 PROTEIN, HUMAN;

ADULT; ARTICLE; BRAZIL; CANCER RISK; CAPILLARY ELECTROPHORESIS; CASE CONTROL STUDY; CONTROLLED STUDY; CUTANEOUS MELANOMA; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; GENETIC PREDISPOSITION; GENETICS; MELANOMA; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SKIN TUMOR;

AROMATASE; BRAZIL; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NF-KAPPA B P50 SUBUNIT; POLYMORPHISM, GENETIC; RISK FACTORS; SKIN NEOPLASMS;

EID: 84965019540     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000267     Document Type: Article

References (32)

1. Badenas C, Aguilera P, Puig-Butillé JA, Carrera C, Malvehy J, Puig S. Genetic counseling in melanoma. Dermatol Ther 2012; 25:397-402.
2. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46:705-716.
3. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14:649-683.
4. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 2001; 107:3-6.
5. Bank S, Skytt Andersen P, Burisch J, Pedersen N, Roug S, Galsgaard J, et al. Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort. PLoS One 2014; 9:e98815.
6. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002; 2:664-674.
7. Ueda Y, Richmond A. NF-kappaB activation in melanoma. Pigment Cell Res 2006; 19:112-124.
8. Yang J, Richmond A. Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res 2001; 61:4901-4909.
9. Huang S, DeGuzman A, Bucana CD, Fidler IJ. Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 2000; 6:2573-2581.
10. Bu H, Rosdahl I, Sun XF, Zhang H. Importance of polymorphisms in NF-kappaB1 and NF-kappaBI alpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol 2007; 133:859-866.
11. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004; 13:35-45.
12. Wang X, Lu P, Xu L, Xu Y, Shi Z, Xu J, et al. Updated meta-analysis of NFkappaB1-94 ins/del ATTG promoter polymorphism and cancer risk based on 19 case-control studies. Asian Pac J Cancer Prev 2011; 12:2479-2484.
13. Nian X, Zhang W, Li L, Sun Y, Sun E, Han R. Meta-analysis of studies on the association between the NF-κB1-94 ins/del ATTG promoter polymorphism and cancer. Tumour Biol 2014; 35:11921-11931.
14. Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998; 90:1039-1071.
15. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994; 15:342-355.
16. Czajka-Oraniec I, Simpson ER. Aromatase research and its clinical significance. Endokrynol Pol 2010; 61:126-134.
17. Santen RJ, Santner SJ, Harvey HA, Lipton A, Simmonds M, Feil PD, et al. Marked heterogeneity of aromatase activity in human malignant melanoma tissue. Eur J Cancer Clin Oncol 1988; 24:1811-1816.
18. Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang L, et al. Human aromatase: gene resequencing and functional genomics. Cancer Res 2005; 65:11071-11082.
19. Huang YC, Chen M, Lin MW, Chung MY, Chang YH, Huang WJ, et al. CYP19 TCT tri-nucleotide Del/Del genotype is a susceptibility marker for prostate cancer in a Taiwanese population. Urology 2007; 69:996-1000.
20. Kim JY, Lee CS, Kim HO, Jo YH, Lee J, Jung MH, et al. The association between genetic polymorphisms in CYP19 and breast cancer risk in Korean women. Oncol Rep 2009; 22:487-492.
21. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004; 96:936-945.
22. Olson JE, Ingle JN, Ma CX, Pelleymounter LL, Schaid DJ, Pankratz VS, et al. A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. Breast Cancer Res Treat 2007; 102:237-247.
23. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
24. Zou YF, Yuan FL, Feng XL, Tao JH, Ding N, Pan FM, et al. Association between NFKB1-94ins/del ATTG promoter polymorphism and cancer risk: a meta-analysis. Cancer Invest 2011; 29:78-85.
25. Yang X, Li P, Tao J, Qin C, Cao Q, Gu J, et al. Association between NFKB1-94 ins/del ATTG promoter polymorphism and cancer susceptibility: an updated meta-analysis. Int J Genomics 2014; 2014:612972.
26. Huo ZH, Zhong HJ, Zhu YS, Xing B, Tang H. Roles of functional NFKB1 and β-TrCP insertion/deletion polymorphisms in mRNA expression and epithelial ovarian cancer susceptibility. Genet Mol Res 2013; 12:3435-3443.
27. Li P, Gu J, Yang X, Cai H, Tao J, Yang X, et al. Functional promoter-94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population. PLoS One 2013; 8:e71604.
28. Jee SH, Lee SY, Chiu HC, Chang CC, Chen TJ. Effects of estrogen and estrogen receptor in normal human melanocytes. Biochem Biophys Res Commun 1994; 199:1407-1412.
29. Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. Ann Oncol 2009; 20:358-364.
30. Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, Straub RH. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 2004; 13:635-638.
31. Riggins RB, Bouton AH, Liu MC, Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm 2005; 71:201-237.
32. Slattery ML, Lundgreen A, Herrick JS, Kadlubar S, Caan BJ, Potter JD, Wolff RK. Variation in the CYP19A1 gene and risk of colon and rectal cancer. Cancer Causes Control 2011; 22:955-963.